Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

Core Viewpoint - Verrica Pharmaceuticals has appointed Dr. Noah L. Rosenberg as Chief Medical Officer, aiming to enhance its clinical programs and establish YCANTH as the standard treatment for molluscum contagiosum [1][2]. Company Overview - Verrica Pharmaceuticals is focused on developing medications for skin diseases requiring medical interventions, with its flagship product YCANTH being the first FDA-approved treatment for molluscum contagiosum [8]. - YCANTH is a drug-device combination product that effectively treats a highly contagious skin disease affecting approximately 6 million people in the U.S., primarily children [7][8]. Appointment of Chief Medical Officer - Dr. Noah L. Rosenberg brings over 30 years of experience in clinical and therapeutic development, having held senior positions in various biotechnology companies [2]. - His previous roles include Chief Medical Officer at Travere Therapeutics and Medimetriks Pharmaceuticals, where he led the development and approval of significant dermatological products [2]. Financial Incentives - As part of his appointment, Dr. Rosenberg was granted a stock option award to purchase 325,000 shares of Verrica's common stock at an exercise price of $0.5221 per share [3][5]. - The stock option will vest over time, with specific conditions tied to Dr. Rosenberg's continued service with the company [6]. Product Development and Market Potential - YCANTH has shown positive results in clinical trials, demonstrating safety and efficacy for treating molluscum contagiosum, with approximately 225 million lives eligible for insurance coverage [7]. - The company is also developing treatments for common warts and has a licensing agreement with Lytix Biopharma to develop VP-315 for non-melanoma skin cancers [8].